RSRegina Stegherr

Regina Stegherr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Regina Stegherr has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Beyersmann

    Institute of Statistics Ulm University Ulm Germany

    6 shared publications
  • Christof Schaefer

    Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Clinical Pharmacology and Toxicology, Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Augustenburger Platz 1, 13353 Berlin, Germany

    3 shared publications
  • Tim Friede

    Department of Medical Statistics University Medical Center Göttingen Göttingen Germany

    3 shared publications
  • Claudia Schmoor

    Clinical Trials Unit Faculty of Medicine and Medical Center—University of Freiburg Freiburg Germany

    2 shared publications
  • Claudia Schmoor

    Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany

    2 shared publications
  • Felix Berger

    Department of Congenital Heart Disease—Pediatric Cardiology, Deutsches Herzzentrum der Charité, Augustenburger Platz 1, 13353 Berlin, Germany

    2 shared publications

Latest Publications

  • Open Access

    Prognostic Value and Sex-Related Differences in Chest Pain in Patients with Acute Pulmonary Embolism: A Prospective Cohort Study Beyond Myocardial Ischemia

    by David Frumkin, Marie C. Merten, Ann-Sophie Eggers, Regina Stegherr, Marieke Lankeit, Markus H. Lerchbaumer, Gerhardt Hindricks, Gerd Hasenfuß, Stavros Konstantinidis, Matthias Ebner

    Background: While previous studies indicate an association between chest pain and favorable clinical outcomes in patients with pulmonary embolism (PE), the extent and underlying mechanisms of this effect remain inadequately defined. Methods: We investigated the prognostic value of chest pain with regard to in-hospital adverse outcomes and the association of chest pain with age and sex in consecutive patients with confirmed PE enrolled in a single-center registry between 2008 and 2019. Results: Of 858 patients (52% female) included in this study, 435 (51%) had chest pain at presentation. Chest pain was more prevalent in younger individuals aged 18–34 years (74%) compared to patients >34 years (46%). The prevalence of coronary artery disease (CAD) was similar in patients with and without chest pain (17.0% vs. 16.1%). Chest pain patients less frequently presented with elevated troponin levels (p < 0.001) or signs of right heart strain (RHS; p = 0.007) but more frequently exhibited imaging signs of pulmonary infarction (p = 0.001). Chest pain was associated with lower risk of adverse outcome (OR 0.35 [95% CI: 0.19–0.65]) and in-hospital mortality (OR 0.31 [95% CI: 0.13–0.74]). Multivariable models confirmed a prognostic effect independent of sex, comorbidities and results of risk stratification algorithms. Conclusions: In acute PE, chest pain is a favorable prognostic marker irrespective of sex. Chest pain patients are less likely to suffer from myocardial ischemia or show signs of RHS but more frequently show imaging signs of pulmonary infarction, suggesting pleuritic irritation rather than myocardial ischemia as the likely cause of pain.

  • Open Access

    Less Invasive Acute Rejection Surveillance After Pediatric Heart Transplantation: Experiences From a Low-intensity Biopsy Center

    by Lisa-Maria Rosenthal, Luisa M. Müller, Michaela M. Msc Freitag, Regina Stegherr, Mustafa Yigitbasi, Frank Konietschke, Oliver Miera, Titus Kühne, Felix Berger, Katharina R.L. Schmitt, et al.

    Background.: Acute rejection remains a leading cause of morbidity and mortality early after pediatric heart transplantation (HT). Current guidelines recommend only endomyocardial biopsies (EMB) as reliable for rejection surveillance. We purposed to explore clinical outcomes of less invasive rejection surveillance in a low-intensity biopsy center in pediatric heart recipients. Methods.: We retrospectively analyzed data from 46 pediatric heart recipients (median age 5.7 y; interquartile range [IQR], 2.5–8.0) discharged between 2011 and 2021. Clinical and echocardiographic evaluations were performed frequently, whereas protocol-based routine EMB were scheduled only at 1 and 2 y post-HT. Additional biopsies were performed if new-onset symptoms and/or a decline in graft function, as assessed by echocardiography, including tissue Doppler imaging (TDI)-derived velocities, were detected. Results.: Graft survival was not compromised by less invasive surveillance with 97.8% at 1 y and 95.7% at 2 y post-HT. A total of 680 echocardiograms (median 15 per recipient; IQR, 13–17) and 140 biopsies (median 3 per recipient; IQR, 2–4) were analyzed. Acute rejection (4 acute cellular rejection and 8 antibody-mediated rejection) was found in 8.5% of the EMB. None of the protocol-based routine EMB of asymptomatic patients revealed rejection. Absence of a reduction in TDI-derived left ventricular and interventricular septal systolic velocities, combined with clinical evaluation, correlated with nonrejection. Conclusions.: Combining frequent clinical follow-up with echocardiographic assessment using TDI as a less invasive method of rejection surveillance did not compromise long-term clinical outcomes. Validated in larger pediatric cohorts, it could save invasive biopsies, reducing the risk of biopsy-related complications and medical costs.

  • Open Access

    Strain Analysis from Transverse CMR Cine Imaging in Congenital Heart Disease: Feasibility, Reproducibility, and Comparison to Global Longitudinal Strain

    by Victoria Zieschang, Peter Kramer, Collin Götze, Sebastian Kelle, Regina Stegherr, Alireza Khasheei, Felix Berger, Johannes Nordmeyer, Titus Kühne, Sarah Nordmeyer, et al.

    Background: Global longitudinal strain (GLS), derived from long-axis cine images (LAX), is a sensitive marker for myocardial dysfunction and a strong predictor for clinical events and future ventricular deterioration. In patients with complex congenital heart disease (CHD) transverse-oriented cine imaging is part of the standard cardiac magnetic resonance (CMR) protocol. We aimed to study the feasibility and reproducibility of strain measurements derived from transverse-oriented cine images (Transverse Strain (TrS)) and compare them with standard GLS. Methods: We retrospectively analyzed CMR cine images from 40 patients (n = 20 Fontan, n = 20 Tetralogy of Fallot (ToF)) and 10 healthy controls. Strain analysis was performed in every subject using both the conventional GLS and the TrS approach. Results: TrS showed high intra- and interobserver reproducibility in patients with CHD (intraclass correlation coefficient (ICC) > 0.75, p < 0.05). Intermethod agreement between TrS and GLS was strong in Fontan patients and in the right ventricle (RV) of ToF patients (ICC > 0.75) but showed a positive bias for TrS in the left ventricle (LV) of ToF patients (mean difference = 5.03) and in both ventricles of healthy controls (mean difference LV = 5.36, RV = 4.01). Conclusions: TrS is feasible and reproducible and may offer a new methodological approach for strain assessment, especially in CHD patients with univentricular physiology and ToF patients. Further studies are needed to validate this new approach and perform correlations to clinical outcomes.

  • Open Access

    Pilot, open, prospective, randomized, multicentre trial on quality assessment of declined liver grafts by normothermic ex vivo machine perfusion for decreasing time to transplantation: study protocol for the ExTra-Trial

    by Simon Moosburner, Igor M. Sauer, Mateja Mandac, Dominik P. Modest, Dario Zocholl, Regina Stegherr, Madhukar S. Patel, Julia Wendon, Christoph Roderburg, Markus Selzner, et al.

    Background Liver transplantation remains the only curative option for end-stage liver disease, yet high waitlist mortality and organ scarcity continue to challenge the field. The randomized multicentric ExTra trial aims to improve donor utilization by evaluating whether normothermic machine perfusion (NMP) allows for safe transplantation of liver grafts that would otherwise be discarded. Methods The ExTra trial is a prospective, randomized, multicentre study conducted across German transplant centres. Participants listed for liver transplantation with a ReMELD-Na-Score ≤ 21 who are not eligible for Standard or Non-Standard Exceptions will be randomized for a one-year intervention period into two groups: the experimental arm, in which they have - in addition to regular organ allocation - the extra option to receive a graft that was initially deemed non-transplantable based on clinical criteria, but meets specified quality criteria after at least four hours of NMP, and the control arm, which consists of conventional allocation procedures alone. The primary endpoint is time-to-transplant, defined as the period between randomization and transplantation. Secondary outcomes include competing events (death, disease progression, or recovery without transplantation), graft and patient survival, quality of life, and cost-effectiveness. Additional analyses will assess early graft function, ICU and hospital stay, biliary complications, and 1-year post-transplant outcomes. A centralized biobank will collect perfusate, tissue, and blood samples for biomarker research. Safety will be monitored through quarterly reviews by the Data and Safety Monitoring Board (DSMB). Discussion The ExTra trial seeks to establish NMP as a tool for improving organ utilization and reducing waitlist mortality by quality assessment of severely marginal liver grafts. Nearly all German transplant centres have expressed their interest in participating, though limited access to NMP devices and lack of reimbursement remain key barriers to broader implementation of this technology in Germany. By generating high-quality clinical and translational data, the trial has the potential to reshape the liver graft allocation process, provide key insights in liver physiology, and contribute to the development of biomarkers for organ assessment by NMP. The findings will be essential for future integration of NMP into clinical routine. Trial registration: ClinicalTrials.gov NCT06874296. Registered March 2025


  • Open Access

    Sarcopenia as a Risk Factor in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Implantation

    by Laura Büttner, Annette Aigner, Regina Stegherr, Simon Iseke, Martin Jonczyk, Willie Magnus Lüdemann, Timo Alexander Auer, Federico Collettini, Dirk Schnapauff, Maximilian de Bucourt, et al.

    Background: Prior studies suggest that patients’ body composition changes following transjugular intrahepatic portosystemic shunt (TIPS) implantation, potentially influencing complications and survival. Method: A prototype artificial intelligence (AI)-based, automated computed tomography (CT) body composition analysis tool was used to assess body composition imaging parameters in pre- and postinterventional scans of TIPS patients: visceral (VAT) and subcutaneous adipose tissue (SAT) areas, psoas muscle area (PMA), and total abdominal muscle area (TAMA). Sarcopenia was defined as a lumbar skeletal muscle index (LSMI) ≤ 38.5 cm2/m2 in women and ≤52.4 cm2/m2 in men. We analyzed longitudinal changes in body composition and investigated the impact of sarcopenia at TIPS implantation on the risk of TIPS thrombosis, hepatic encephalopathy, complications, and death using Cox regression models. Results: No clear trend emerged regarding changes in body composition parameters during postinterventional follow-up. Sarcopenia at TIPS implantation increased the instantaneous risk of postinterventional complications (hazard ratio (HR) 1.67; 95% confidence interval (CI) 0.95–2.93), development of hepatic encephalopathy (HR 1.65; 0.81–3.33), as well as the risk of dying within one year (HR 1.39; 0.66–2.92). Conclusions: CT body composition analysis may help in identifying high-risk patients undergoing TIPS implantation. Sarcopenia was associated with increased mortality and a higher incidence of postinterventional complications, particularly hepatic encephalopathy.


  • Open Access

    App- and Wearable-Based Remote Monitoring for Patients With Myasthenia Gravis and Its Specialists: Feasibility and Usability Study

    by Maike Stein, Regina Stegherr, Pushpa Narayanaswami, David Legg, Meret Herdick, Andreas Meisel, Lea Gerischer, Sophie Lehnerer

    Background: Myasthenia gravis (MG) is rare, chronic autoimmune disorder of the neuromuscular junction that requires specialized care and often lifelong treatment, facing challenges due to its rarity and the limited availability of specialists. Telemedical solutions in specialized centers hold considerable promise in bridging this gap by increasing access to this care to a broader patient population in a timely manner. However, there is no research regarding interventional remote care solutions in the field of MG to date. Objective: This study aimed to assess the feasibility and usability among patients with MG and specialists of a telemedicine platform, tailored to patients with MG and designed to facilitate remote monitoring, treated in a specialized center. Methods: The telemedicine platform consisted of an app for patients and a web-based portal for physicians. Over a period of 3 months, 30 patients continuously monitored their vital parameters through external devices, including a digital spirometer and a wearable (activity tracker). Furthermore, patients completed 7 different patient-reported outcome measures (PROMs) through the app at predefined intervals. Specialists could review this monitoring data and adjust therapy as necessary. In addition, communication between patients and physicians was facilitated through a chat module. Feasibility was evaluated by total adherence rates for completing PROMs within the app, alongside the collection of spirometry and wearable data. Furthermore, user satisfaction was assessed among both patients with MG and physicians at the end of study. Results: Total adherence rates ranged from 74.3% (1830/2464) to 97.9% (327/334) across all data types, with the highest adherence observed for PROMs (1139/1179, 96.6%), followed by spirometry (293/334, 87.7%) and wearables (1830/2261, 80.9%). Notably, patients wore the wearable longer than required by protocol and conducted a higher number of spirometry measurements during the study than required per protocol (median 20 h/d [IQR 15-24] vs 14 h/d and median 49 [IQR 15-59] measurements vs 11 measurements, respectively). Technical issues and discomfort with wearables were factors affecting lower adherence in some patients. The System Usability Scale yielded a median score of 85 indicating “excellent usability.” In addition, results from a more detailed user evaluation questionnaire showed high levels of user satisfaction among both patients and health care professionals across diverse categories, including their experience of the care program, communication, and evaluation of the program. Conclusions: Remote monitoring of patients with MG through the telemedical platform demonstrated good feasibility and acceptability, as evidenced by above-average adherence rates and user satisfaction for both patients and physicians. The majority of patients wanted to continue using the app. These findings highlight the potential for user-friendly digital tools to enhance care for patients with MG, although addressing technical challenges and ensuring patient comfort with wearables are essential for optimal implementation. Further research involving larger cohorts and longer study duration is warranted to validate these findings.


  • Open Access

    How to account for early overly small risk sets in the analysis of pregnancy outcome data?—Comparison of different methods for stabilizing the Aalen‐Johansen estimator

    by Regina Stegherr, Anne‐Katrin Fietz, Maria Hoeltzenbein, Katarina Dathe, Jan Beyersmann

    Purpose: In analyzing pregnancy data concerning drug exposure in the first trimester, the risk of spontaneous abortions is of primary interest. For estimating the cumulative incidence function, the Aalen–Johansen estimator is typically used, and competing risks such as induced abortion and livebirth are considered. However, the delayed study entry can lead to overly small risk sets for the first events. This results in large jumps in the estimated cumulative incidence function of spontaneous abortions or induced abortions using the Aalen–Johansen estimator, and consequently in an overestimation of the probability.Methods: Several approaches account for early overly small risk sets. The first approach is conditioning on the event time being greater than the event time causing the large jump. Second, the events can be ignored by censoring them. Third, the events can be postponed until a large enough number is at risk. These three approaches are compared.Results: All approaches are applied using data of 54 lacosamide‐exposed pregnancies. The Aalen–Johansen estimate of the probability of spontaneous abortion is 22.64%, which is relatively large for only three spontaneous abortions in the dataset. The conditional approach and the ignore approach have an estimated probability of 7.17%. In contrast, the estimate of the postpone approach is 16.45%. In this small sample, bootstrapped confidence intervals seem more accurate.Conclusions: In the analyses of pregnancy data with rare events, the postpone approach is favorable as no events are excluded. However, the approach that ignores early events has the narrowest confidence interval.


  • Open Access

    Modeling unmeasured baseline information in observational time-to-event data subject to delayed study entry

    by Regina Stegherr, Jan Beyersmann, Peter Bramlage, Tobias Bluhmki

    Unmeasured baseline information in left-truncated data situations frequently occurs in observational time-to-event analyses. For instance, a typical timescale in trials of antidiabetic treatment is “time since treatment initiation”, but individuals may have initiated treatment before the start of longitudinal data collection. When the focus is on baseline effects, one widespread approach is to fit a Cox proportional hazards model incorporating the measurements at delayed study entry. This has been criticized because of the potential time dependency of covariates. We tackle this problem by using a Bayesian joint model that combines a mixed-effects model for the longitudinal trajectory with a proportional hazards model for the event of interest incorporating the baseline covariate, possibly unmeasured in the presence of left truncation. The novelty is that our procedure is not used to account for non-continuously monitored longitudinal covariates in right-censored time-to-event studies, but to utilize these trajectories to make inferences about missing baseline measurements in left-truncated data. Simulating times-to-event depending on baseline covariates we also compared our proposal to a simpler two-stage approach which performed favorably. Our approach is illustrated by investigating the impact of baseline blood glucose levels on antidiabetic treatment failure using data from a German diabetes register.


  • Increasing use of newer antiseizure medication during pregnancy: An observational study with special focus on lacosamide

    by Maria Hoeltzenbein, Sofia Slimi, Anne-Katrin Fietz, Regina Stegherr, Marlies Onken, Jan Beyersmann, Katarina Dathe, Christof Schaefer